ATE516853T1 - Zyklische peptid-cxcr4-antagonisten - Google Patents

Zyklische peptid-cxcr4-antagonisten

Info

Publication number
ATE516853T1
ATE516853T1 AT08769524T AT08769524T ATE516853T1 AT E516853 T1 ATE516853 T1 AT E516853T1 AT 08769524 T AT08769524 T AT 08769524T AT 08769524 T AT08769524 T AT 08769524T AT E516853 T1 ATE516853 T1 AT E516853T1
Authority
AT
Austria
Prior art keywords
cyclic peptide
cxcr4 antagonists
peptide cxcr4
antagonists
cyclic
Prior art date
Application number
AT08769524T
Other languages
German (de)
English (en)
Inventor
Wayne Kohn
Sheng-Bin Peng
Liang Yan
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39831600&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE516853(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of ATE516853T1 publication Critical patent/ATE516853T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • AIDS & HIV (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT08769524T 2007-05-30 2008-05-20 Zyklische peptid-cxcr4-antagonisten ATE516853T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94080207P 2007-05-30 2007-05-30
US94099607P 2007-05-31 2007-05-31
PCT/US2008/064177 WO2008150689A1 (en) 2007-05-30 2008-05-20 Cyclic peptide cxcr4 antagonists

Publications (1)

Publication Number Publication Date
ATE516853T1 true ATE516853T1 (de) 2011-08-15

Family

ID=39831600

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08769524T ATE516853T1 (de) 2007-05-30 2008-05-20 Zyklische peptid-cxcr4-antagonisten

Country Status (32)

Country Link
US (3) US7691813B2 (enExample)
EP (2) EP2160221B1 (enExample)
JP (1) JP5358564B2 (enExample)
KR (2) KR101169846B1 (enExample)
CN (1) CN101678213B (enExample)
AR (1) AR066648A1 (enExample)
AT (1) ATE516853T1 (enExample)
AU (1) AU2008260326B2 (enExample)
BR (1) BRPI0812134A2 (enExample)
CA (1) CA2688574C (enExample)
CL (1) CL2008001467A1 (enExample)
CO (1) CO6241137A2 (enExample)
CR (1) CR11105A (enExample)
CY (1) CY1111815T1 (enExample)
DK (1) DK2160221T3 (enExample)
DO (1) DOP2009000270A (enExample)
EA (1) EA017716B1 (enExample)
GT (1) GT200900304A (enExample)
HR (1) HRP20110551T1 (enExample)
IL (1) IL201685A (enExample)
JO (1) JO2776B1 (enExample)
MA (1) MA31666B1 (enExample)
MX (1) MX2009012952A (enExample)
MY (1) MY149432A (enExample)
NZ (1) NZ580849A (enExample)
PE (1) PE20090299A1 (enExample)
PL (1) PL2160221T3 (enExample)
PT (1) PT2160221E (enExample)
TN (1) TN2009000496A1 (enExample)
TW (1) TWI423987B (enExample)
WO (1) WO2008150689A1 (enExample)
ZA (1) ZA200908345B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2942798B1 (fr) * 2009-03-05 2011-04-08 Centre Nat Rech Scient Peptides utilisables pour le traitement de la leucemie lymphoide chronique
IT1397901B1 (it) * 2010-01-26 2013-02-04 Consiglio Nazionale Ricerche Peptidi ciclici che legano il recettore cxcr4 e relativi usi in campo medico e diagnostico.
WO2012118124A1 (ja) * 2011-03-01 2012-09-07 国立大学法人京都大学 新規ケモカイン受容体拮抗剤
MX343205B (es) * 2011-06-07 2016-10-28 Polyphor Ag Peptidomiméticos de horquilla beta como antagonistas de cxc4.
WO2013044500A1 (zh) * 2011-09-30 2013-04-04 Cheng Yun 丙型肝炎病毒免疫原性肽或其衍生物在预防或治疗关节炎中的应用
CA2852160A1 (en) 2011-10-28 2013-05-02 Galderma Research & Development New leukocyte infiltrate markers for rosacea and uses thereof
EP2979991A1 (en) 2014-07-31 2016-02-03 Greif International Holding BV. Multilayer material, fire protection mat with said multilayer material and transport and storage container assembly comprising said fire protection mat.
ES2764840T3 (es) 2015-01-28 2020-06-04 Univ Bordeaux Uso de plerixafor para tratar y/o prevenir exacerbaciones agudas de la enfermedad pulmonar obstructiva crónica
WO2017176565A1 (en) 2016-04-07 2017-10-12 Eli Lilly And Company Combinations of an anti-b7-h1 antibody and a cxcr4 peptide antagonist for treating a solid tumor
EP3509612A4 (en) * 2016-09-06 2021-07-21 Mainline Biosciences CXCR4 ANTAGONISTS AND METHOD OF USE
CN106841624B (zh) * 2017-01-26 2019-02-22 庄磊靓 抗人cd4和抗人cd184单克隆抗体作为标志物的应用
KR20200043970A (ko) * 2017-09-05 2020-04-28 메인라인 바이오사이언스 고친화성 cxcr4 선택적 결합 콘쥬게이트 및 그 사용 방법
US11123437B2 (en) * 2017-09-05 2021-09-21 Mainline Biosciences, Inc. Selective CXCR4 binding peptide conjugate and methods for making and using the same
US11771736B2 (en) * 2017-12-21 2023-10-03 Mainline Biosciences (Shanghai) Co., Ltd. Composition comprising a therapeutic agent and a CXCR4 selective antagonist and methods for using the same
JP2021165234A (ja) * 2018-07-03 2021-10-14 富士フイルム富山化学株式会社 Cxcr4結合性化合物もしくはその塩またはそれらと金属との錯体
EP3849997B1 (en) 2018-09-12 2024-05-01 Technische Universität München Cxcr4-targeted diagnostic and therapeutic agents with reduced species selectivity
EA202190755A1 (ru) 2018-09-12 2021-06-11 Технише Универзитет Мюнхен Агенты для терапии и диагностики рака
WO2020210919A1 (en) * 2019-04-18 2020-10-22 Provincial Health Services Authority Novel radiolabelled cxcr4-targeting compounds for diagnosis and therapy
EP4097120A4 (en) * 2020-01-26 2024-05-01 Mainline Biosciences (Shanghai) Co., Ltd. ISOTOPE-LABELED CXCR4 SELECTIVELY BINDING PEPTIDE CONJUGATE AND METHODS OF MAKING AND USE THEREOF
WO2022082312A1 (en) * 2020-10-21 2022-04-28 Provincial Health Services Authority Novel cxcr4-targeting compounds
CN116615411A (zh) * 2020-12-25 2023-08-18 中外制药株式会社 包含n-取代氨基酸残基的肽化合物的制造方法
WO2022138891A1 (ja) * 2020-12-25 2022-06-30 中外製薬株式会社 N-置換-アミノ酸残基を含むペプチド化合物の製造方法
EP4043041A1 (en) 2021-02-15 2022-08-17 Technische Universität München Cxcr4-ligands for diagnostic and therapeutic use and precursors thereof
JP2025513489A (ja) * 2022-04-20 2025-04-24 プロビンシャル・ヘルス・サービシーズ・オーソリティ Cxcr4標的化合物、およびその作製方法、およびその使用方法
CN115060901A (zh) * 2022-06-21 2022-09-16 中国医学科学院基础医学研究所 苹果酸酶2在制备矽肺病或肺纤维化相关疾病诊断试剂或治疗药物中的应用
WO2025218761A1 (zh) * 2024-04-17 2025-10-23 晶核生物医药科技(上海)有限公司 环状肽类化合物、其药物组合物及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4391123B2 (ja) * 2002-10-24 2009-12-24 株式会社オーファンリンク 新規cxcr4アンタゴニスト
US8628750B2 (en) * 2006-02-27 2014-01-14 Technische Universitat Munchen Cancer imaging and treatment

Also Published As

Publication number Publication date
KR20100003737A (ko) 2010-01-11
ZA200908345B (en) 2011-02-23
EP2160221A1 (en) 2010-03-10
CA2688574C (en) 2014-02-18
TN2009000496A1 (en) 2011-03-31
USRE42274E1 (en) 2011-04-05
GT200900304A (es) 2011-11-09
CN101678213A (zh) 2010-03-24
MY149432A (en) 2013-08-30
EP2160221B1 (en) 2011-07-20
CL2008001467A1 (es) 2008-12-05
AU2008260326B2 (en) 2011-07-21
TW200902556A (en) 2009-01-16
CO6241137A2 (es) 2011-01-20
CN101678213B (zh) 2013-11-06
US20100130409A1 (en) 2010-05-27
US7691813B2 (en) 2010-04-06
WO2008150689A1 (en) 2008-12-11
AR066648A1 (es) 2009-09-02
BRPI0812134A2 (pt) 2014-11-18
CR11105A (es) 2010-04-12
EA017716B1 (ru) 2013-02-28
EA200971129A1 (ru) 2010-04-30
PE20090299A1 (es) 2009-03-19
TWI423987B (zh) 2014-01-21
KR20110134519A (ko) 2011-12-14
HK1141474A1 (en) 2010-11-12
US20080300177A1 (en) 2008-12-04
CY1111815T1 (el) 2015-10-07
JP2010529957A (ja) 2010-09-02
DOP2009000270A (es) 2010-01-15
KR101319740B1 (ko) 2013-10-17
JP5358564B2 (ja) 2013-12-04
KR101169846B1 (ko) 2012-08-01
AU2008260326A1 (en) 2008-12-11
NZ580849A (en) 2012-03-30
MA31666B1 (fr) 2010-09-01
CA2688574A1 (en) 2008-12-11
IL201685A (en) 2015-04-30
IL201685A0 (en) 2010-05-31
HRP20110551T1 (hr) 2011-09-30
JO2776B1 (en) 2014-03-15
PT2160221E (pt) 2011-09-12
PL2160221T3 (pl) 2011-12-30
DK2160221T3 (da) 2011-09-19
EP2377579A1 (en) 2011-10-19
MX2009012952A (es) 2009-12-11

Similar Documents

Publication Publication Date Title
DK2160221T3 (da) Cykliske peptid-CXCR4-antagonister
HUS2200025I1 (hu) C5AR antagonisták
HRP20151108T1 (xx) Antagonisti nogo-receptora
PL2465864T3 (pl) Szczepionki z peptydem pochodzącym z Eph4
BRPI0911743A2 (pt) "peptídeo"
DK3115370T3 (da) Biologisk aktive peptider
DK2443104T3 (da) Disubstituerede phthalazin-hedgehog-sti-antagonister
EP2276499A4 (en) ANTIGEN OF RECOMBINANT GLIADINE DEAMIDED
ZA201000776B (en) Cyclic depsipeptides
BRPI0810203A2 (pt) Compostos peptídeos cíclicos.
BR112012003701A2 (pt) "novos antagonistas de quinolina-hepcidina"
BRPI0817835A2 (pt) Antagonistas cgrp
EP2236266A4 (en) Injector
DK2364185T3 (da) Disubstituerede phthalazin-hedgehog-pathway-antagonister
DK2799428T3 (da) Glucagon-antagonister
BRPI1010661A2 (pt) peptídeo
DK2131818T3 (da) Ny doseringsform
EP2101804A4 (en) PROANGIOGENIC PEPTIDES
BRPI0908008A2 (pt) Farmacóforo dual - pde4-antagonistas muscarínicos
EP2280988A4 (en) ANGIOGENIC PEPTIDE
DK2257534T3 (da) 3-aminoalkyl-1,4-diazepan-2-on-melanocortin-5-receptorantagonister
BRPI0907519A2 (pt) Antagonistas farmacoforos-pde4-muscarínicos duais
EP2370100A4 (en) PEPTIDE AGENTS
EP2252310A4 (en) HETEROCYCLIC PEPTIDE KETOAMIDE
FR2940520B1 (fr) Structure semiconductrice

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2160221

Country of ref document: EP